Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1013114

registered interest
date	23/11/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Money Laundering: Criminal Investigation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, how many of the investigations into high-end money laundering opened by the National Crime Agency have resulted in charging decisions since 2014.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	195062
answer	answer is ministerial correction date of answer 29/01/2019 answer text <p>The number of investigations into high end money laundering opened by the National Crime Agency which have resulted in charging decisions since 2014 are as follows:</p><p>• 2014/15 – 34</p><p>• 2015/16 – 17</p><p>• 2016/17 – 8</p><p>• 2018/19 – 10</p> answering member constituency Wyre and Preston North answering member printed Mr Ben Wallace question first answered 29/01/2019 10:19:12 answering member 1539 label Biography information for Mr Ben Wallace
tabling member	4125 label Biography information for Catherine McKinnell

1013091

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Complex Regional Pain Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps his Department has taken to improve the (a) diagnosis, (b) treatment and (c) awareness among medical professionals of Complex Regional Pain Syndrome in (i) Oxfordshire and (ii) England.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	195086
answer	answer is ministerial correction date of answer 03/12/2018 answer text <p>To support clinicians in diagnosing and managing complex regional pain syndrome, guidance on the condition is available from a variety of authoritative professional sources. Advice from the Royal National Hospital for Rheumatic Diseases and a copy of the Royal College of Physicians guidance can be found at the following links:</p><p> </p><p><a href="http://www.rcplondon.ac.uk/guidelines-policy/complex-regional-pain-syndrome-adults" target="_blank">www.rcplondon.ac.uk/guidelines-policy/complex-regional-pain-syndrome-adults</a></p><p> </p><p><a href="http://www.rnhrd.nhs.uk/page/79" target="_blank">www.rnhrd.nhs.uk/page/79</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/12/2018 17:08:43 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran

1013140

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what NHS England’s specialised commissioning drug spend was in (a) 2014-15, (b) 2016-17 and (c) 2017-18; what proportion of that spend was accounted for by the (i) top 10 highest spend drugs and (ii) top 20 highest spend drugs in each year; and if he will list the (A) top 10 and (B) top 20 highest spend drugs in each year.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	195065
answer	answer is ministerial correction date of answer 28/11/2018 answer text <p>The 2014/15 specialised commissioning drug spend totalled approximately £3.0 billion. Top 10 and top 20 highest spend drug data is not available for 2014/15.</p><p> </p><p>The 2016/17 specialised commissioning drug spend totalled approximately £3.6 billion. The top 10 highest spend drugs accounted for approximately 28% of specialised commissioning total drug spend. The top 20 highest spend drugs accounted for approximately 42% of specialised commissioning total drug spend. The top 10 and top 20 highest spend drugs are listed in the attached document.</p><p> </p><p>The 2017/18 specialised commissioning drug spend totalled approximately £3.9 billion. The top 10 highest spend drugs accounted for approximately 28% of specialised commissioning total drug spend. The top 20 highest spend drugs accounted for approximately 43% of specialised commissioning total drug spend. The top 10 and top 20 highest spend drugs for 2017/18 are also listed in the attached document.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/11/2018 17:26:58 answering member 4067 label Biography information for Steve Brine attachment 1 file name PQ195065 tables.docx title PQ195065 attached table
tabling member	4244 label Biography information for Jonathan Ashworth

1013141

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much was spent on medicines included in the Pharmaceutical Price Regulation Scheme (PPRS) in each year since 2010; what proportion of his Department’s budget was spent on medicines included in PPRS in each year of those years; and what proportion of NHS England's budget spent was on medicines included in PPRS in each year since 2013.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	195066
answer	answer is ministerial correction date of answer 28/11/2018 answer text <p>The years 2010 to 2012 are fully covered by the 2009 Pharmaceutical Price Regulation Scheme (PPRS). There is no available data of the aggregate net sales during this period as they were not collected as part of the 2009 PPRS.</p><p> </p><p>However, aggregate net sales covered by the PPRS in the 2014 scheme are available and published quarterly by the Department. The years 2014 to 2018 are covered by the 2014 PPRS, with full year data up to 2017 currently available. The aggregate net sales made in 2013 (the base year of the 2014 PPRS) is also available.</p><p> </p><p>The most recently data is as of August 2018, and was published in October 2018 and can be found at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/pprs-aggregate-net-sales-and-payment-information-august-2018" target="_blank">https://www.gov.uk/government/publications/pprs-aggregate-net-sales-and-payment-information-august-2018</a></p><p> </p><p>The following table uses the published data mentioned above, and shows the aggregate net sales covered by the 2014 PPRS for the United Kingdom by calendar year. A ratio of 0.8 has been applied to the UK aggregate sales to calculate an estimate of the England aggregate sales.</p><p> </p><p>Aggregate sales covered by the 2014 PPRS</p><p><strong> </strong></p><table><tbody><tr><td><p> </p></td><td><p>UK (£ million)</p></td><td><p>England (£ million)</p></td></tr><tr><td><p>2013</p></td><td><p>7,901</p></td><td><p>6,321</p></td></tr><tr><td><p>2014</p></td><td><p>8,340</p></td><td><p>6,672</p></td></tr><tr><td><p>2015</p></td><td><p>8,173</p></td><td><p>6,538</p></td></tr><tr><td><p>2016</p></td><td><p>8,060</p></td><td><p>6,450</p></td></tr><tr><td><p>2017</p></td><td><p>8,198</p></td><td><p>6,530</p></td></tr></tbody></table><p> </p><p>The sales figures do not fully represent total costs borne to the Department or NHS England. They are gross of any payments received by the Department under the 2014 PPRS, and do not include costs such as wholesaler margin or VAT. As such no direct comparison should be made to budgeting totals.</p><p> </p><p>The following table shows the Department of Health and Social Care Departmental Expenditure Limit in financial years.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Department of Health and Social Care Departmental Expenditure Limit (£ million)</p></td></tr><tr><td><p>2010/11</p></td><td><p>100,400</p></td></tr><tr><td><p>2011/12</p></td><td><p>102,800</p></td></tr><tr><td><p>2012/13</p></td><td><p>105,200</p></td></tr><tr><td><p>2013/14</p></td><td><p>109,800</p></td></tr><tr><td><p>2014/15</p></td><td><p>113,300</p></td></tr><tr><td><p>2015/16</p></td><td><p>117,200</p></td></tr><tr><td><p>2016/17</p></td><td><p>120,600</p></td></tr><tr><td><p>2017/18</p></td><td><p>125,200</p></td></tr></tbody></table><p> </p><p>The following table show the levels of NHS England funding, by financial year. NHS England was created in October 2012, and its first full set of accounts was in 2013/2014.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>NHS England Funding (£ million)</p></td></tr><tr><td><p>2013/14</p></td><td><p>93,900</p></td></tr><tr><td><p>2014/15</p></td><td><p>97,300</p></td></tr><tr><td><p>2015/16</p></td><td><p>100,500</p></td></tr><tr><td><p>2016/17</p></td><td><p>106,000</p></td></tr><tr><td><p>2017/18</p></td><td><p>109,800</p></td></tr></tbody></table><p> </p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/11/2018 17:23:23 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

1013144

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Attendance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of patients had access to evening and weekend GP appointments at (a) March 2018 and (b) October 2018.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	195069
answer	answer is ministerial correction date of answer 05/12/2018 answer text <p>The Government has committed to ensuring that everyone can see their general practitioner at a convenient time by increasing the availability of routine appointments in general practice in the evening and at the weekend.</p><p> </p><p>By March 2019, all clinical commissioning groups (CCGs) should provide extended access to general practice for the whole of their registered population, subject to local demand. This includes ensuring that access is available during peak times of demand, including bank holidays and across the Easter, Christmas and New Year periods. This deadline was brought forward to 1 October 2018 in the latest National Health Service planning guidance, which was published by NHS England in February 2018, to ensure additional capacity is in place ahead of winter 2018.</p><p> </p><p>The delivery of the commitment is assessed in two ways, which use different measures of extended access.</p><p> </p><p>The first measure relies on NHS England’s bi-annual survey of extended access, which collects data direct from general practices. This showed that, in September 2018, full extended access was available to 30.8 million registered patients, comprising 55.3% of all registered patients in England. This represents widening of coverage since March 2018, when the previous bi-annual survey found that full extended access was available to 22.6 million, or (39.7%) registered patients. The next bi-annual survey, to be published in April 2019, will show the extent of coverage in March 2019.</p><p> </p><p>The second measure uses the General Practice Forward View Monitoring Survey, which is a monthly return from CCGs that covers all extended access provision, including that delivered via extended access hubs. The results are published via the CCG Improvement and Assessment Framework. The latest data show that, in August 2018, full extended access was available to 40 million registered patients comprising 68% of the registered patient population. This also represents a widening of access relative to March 2018, when full extended access was available to 35.4 million registered patients, comprising 61% of the registered patient population. Data for September and October 2018 are not yet available.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/12/2018 12:29:06 answering member 4067 label Biography information for Steve Brine previous answer version 87857 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

1013146

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish all data collected by his Department relating to waiting lists for contraceptive provision in (a) GP practices and (b) community sexual and reproductive health services.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	195070
answer	answer is ministerial correction date of answer 03/12/2018 answer text <p>Data on waiting lists for contraceptive provision is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/12/2018 17:03:30 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

1013147

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Contraceptives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the average spend per woman on prescribed contraceptive services is by (a) local authority, (b) clinical commissioning group and (c) parliamentary constituency.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	195071
answer	answer is ministerial correction date of answer 03/12/2018 answer text <p>This information is not collected centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/12/2018 17:07:11 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

1013181

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pneumococcal Diseases: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 October to Question 180205 on Pneumococcal Diseases: Vaccination, whether his Department will make the modelling paper available to stakeholders ahead of (a) any decision on a change to the pneumococcal vaccination schedule and (b) ahead of its publication in a peer reviewed journal.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	195079
answer	answer is ministerial correction date of answer 03/12/2018 answer text <p>The modelling prepared by Public Health England which supported the Joint Committee on Vaccination and Immunisation recommendation to move to a 1+1 schedule for Pneumococcal Conjugate Vaccine has been submitted for publication in a peer reviewed journal, and will be published in due course.</p><p> </p><p>There are no plans to share the paper with stakeholders ahead of publication.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/12/2018 17:09:32 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

1013182

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Cost Effectiveness
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 October 2018 to Question 181572 on Drugs: Cost Effectiveness, if he will place in the Library the 27 topics that have triggered the £20 million budget impact test.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	195080
answer	answer is ministerial correction date of answer 03/12/2018 answer text <p>The information requested can be found in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Topic Title</p></td><td><p>Programme</p></td></tr><tr><td><p>1</p></td><td><p>Afamelanotide for treating erythropoietic protoporphyria [ID927]</p></td><td><p>HST (highly specialised technology)</p></td></tr><tr><td><p>2</p></td><td><p>Niraparib for maintenance treatment of platinum-sensitive ovarian cancer after second response to chemotherapy [ID1041]</p></td><td><p>TA (technology appraisal)</p></td></tr><tr><td><p>3</p></td><td><p>Lenalidomide for previously untreated multiple myeloma [ID474]</p></td><td><p>TA</p></td></tr><tr><td><p>4</p></td><td><p>Dupilumab for treating moderate to severe atopic dermatitis after topical treatments [ID1048]</p></td><td><p>TA</p></td></tr><tr><td><p>5</p></td><td><p>Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (Cancer Drugs Fund Review of TA447) [ID1349]</p></td><td><p>TA</p></td></tr><tr><td><p>6</p></td><td><p>Abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945]</p></td><td><p>TA</p></td></tr><tr><td><p>7</p></td><td><p>Pertuzumab for adjuvant treatment of early HER2-positive breast cancer [ID1192]</p></td><td><p>TA</p></td></tr><tr><td><p>8</p></td><td><p>Burosumab for treating X-linked hypophosphataemia [ID1151]</p></td><td><p>HST</p></td></tr><tr><td><p>9</p></td><td><p>Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after two or more systemic therapies [ID1115]</p></td><td><p>TA</p></td></tr><tr><td><p>10</p></td><td><p>Ocrelizumab for treating primary progressive multiple sclerosis [ID938]</p></td><td><p>TA</p></td></tr><tr><td><p>11</p></td><td><p>Daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974]</p></td><td><p>TA</p></td></tr><tr><td><p>12</p></td><td><p>Nusinersen for treating spinal muscular atrophy [ID1069]</p></td><td><p>TA</p></td></tr><tr><td><p>13</p></td><td><p>Dabrafenib in combination with trametinib for adjuvant treatment of resected BRAF V600 positive malignant melanoma [ID1226]</p></td><td><p>TA</p></td></tr><tr><td><p>14</p></td><td><p>Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316]</p></td><td><p>TA</p></td></tr><tr><td><p>15</p></td><td><p>Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (including a review of TA381) [ID1296]</p></td><td><p>TA</p></td></tr><tr><td><p>16</p></td><td><p>Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies [ID1166]</p></td><td><p>TA</p></td></tr><tr><td><p>17</p></td><td><p>Abemaciclib with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer [ID1227]</p></td><td><p>TA</p></td></tr><tr><td><p>18</p></td><td><p>Pembrolizumab for adjuvant treatment of melanoma with high risk of recurrence [ID1266]</p></td><td><p>TA</p></td></tr><tr><td><p>19</p></td><td><p>Human alpha1-proteinase inhibitor for treating emphysema [ID856]</p></td><td><p>HST</p></td></tr><tr><td><p>20</p></td><td><p>Pembrolizumab with pemetrexed and platinum chemotherapy for untreated metastatic non-squamous non-small-cell lung cancer [ID1173]</p></td><td><p>TA</p></td></tr><tr><td><p>21</p></td><td><p>Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]</p></td><td><p>TA</p></td></tr><tr><td><p>22</p></td><td><p>Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]</p></td><td><p>TA</p></td></tr><tr><td><p>23</p></td><td><p>Patisiran for treating hereditary transthyretin amyloidosis [ID1279]</p></td><td><p>HST</p></td></tr><tr><td><p>24</p></td><td><p>Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210]</p></td><td><p>TA</p></td></tr><tr><td><p>25</p></td><td><p>Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID1175]</p></td><td><p>New TA process</p></td></tr><tr><td><p>26</p></td><td><p>Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]</p></td><td><p>New TA process</p></td></tr><tr><td><p>27</p></td><td><p>Enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359]</p></td><td><p>TA</p></td></tr></tbody></table><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/12/2018 17:38:05 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

1013078

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Property
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the sale value of NHS property has been since Sir Robert Naylor's review of NHS Property and estates; and what recent estimate he has made of the sale value of NHS property due to be sold.
tabling member constituency	Hyndburn
tabling member printed	Graham P Jones
uin	195052
answer	answer is ministerial correction date of answer 28/11/2018 answer text <p>The latest published data shows that National Health Service trusts, foundation trusts and the Department, including its arm’s-length bodies and wholly owned property companies, disposed of 301 surplus sites between April 2015 and March 2017, generating £439 million in receipts from unconditional sales. This data is available online, as part of Cabinet Office’s ‘Transparency Report: Government’s land and property disposals in 2015-16 and 2016-17’, published in April 2018 at the following link:</p><p> </p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/697773/Transparency_report_Government_s_land_and_property_disposals_2015-16_and_2016-17__1_.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/697773/Transparency_report_Government_s_land_and_property_disposals_2015-16_and_2016-17__1_.pdf</a></p><p> </p><p>Similar data relating to the 2017-18 financial year will be published in due course.</p><p> </p><p>The Department annually collects data on properties owned by NHS trusts and foundation trusts which has been declared surplus and planned for future disposal. This collection does not include properties owned by the Department, its arm’s-length bodies and wholly owned property companies. Information reported directly by trusts show that as at 31 March 2018 the total declared market value of surplus and potentially surplus land was £260 million; however, many organisations were not able to provide figures due to data limitations, including commercial confidentiality. This data is available at the following link:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-surplus-land/2017-18-england" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-surplus-land/2017-18-england</a></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 28/11/2018 17:48:49 answering member 1585 label Biography information for Stephen Hammond
tabling member	3999 label Biography information for Graham P Jones